Answers are grounded in this paper and cite their sources.
Sodium-glucose cotransporter 2 (SGLT2) inhibitors protect kidney function in diabetic and non-diabetic chronic kidney disease. By reducing proximal sodium-glucose transport, they initiate nephron-wide adaptations in transport workload, solute delivery, oxygen demand, tubuloglomerular feedback, glomerular vascular tone, and metabolic and inflammatory signaling. These responses may reduce mitochondrial stress, ferroptosis, inflammation, maladaptive repair, and fibrosis, while natriuresis, altered substrate use, and cardiac unloading provide additional protection. Although large outcome trials establish clinical efficacy, the contributions of individual pathways remain uncertain and may vary with diabetes type, nephron number, disease stage, and background therapy. This review integrates experimental and clinical evidence into a multiscale physiological model, distinguishes established effects from mechanistic hypotheses, and identifies priorities for physiological phenotyping, spatial and single-cell profiling, biomarker-guided combination therapy, and causal systems-level studies.
No takes yet. Share an insight, caveat, or question.
Hocher et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: